Welcome to our dedicated page for Pacira Biosciences news (Ticker: PCRX), a resource for investors and traders seeking the latest updates and insights on Pacira Biosciences stock.
Overview
Pacira BioSciences Inc (NASDAQ: PCRX) is a specialty pharmaceutical company committed to revolutionizing pain management by offering innovative non-opioid therapies and regenerative health solutions. With a core focus on providing safe and effective alternatives for pain control, the company leverages its proprietary drug delivery platforms to address acute pain in surgical and chronic conditions. Its approach combines advanced pharmaceutical formulations with novel medical devices, ensuring that clinicians have access to effective treatment options that reduce reliance on opioids.
Core Technologies and Products
At the heart of Pacira's innovation is its unique product delivery technology, which encapsulates active compounds without altering their molecular structures. This platform enables controlled, extended release of medications, ensuring long-lasting efficacy. The company has successfully commercialized several non-opioid treatments:
- EXPAREL: A long-acting local anesthetic designed to provide postsurgical pain control through sustained drug release, thereby reducing the need for opioids.
- ZILRETTA: An extended-release intra-articular injection indicated for the management of osteoarthritis knee pain, offering patients prolonged relief.
- iovera®: A handheld, drug-free device that applies controlled doses of cold therapy to targeted nerves, providing immediate and lasting pain relief.
In addition to these commercial products, Pacira is advancing its pipeline with a novel gene therapy candidate, PCRX-201. This locally administered therapy aims to treat osteoarthritis by regulating inflammatory pathways, thus addressing the root causes of pain and disability.
Market Position and Business Model
Pacira BioSciences operates at the intersection of innovative drug delivery and non-opioid pain management solutions. Its business model emphasizes:
- Commercialization of Proven Therapies: The company has established a presence in markets requiring effective postsurgical and chronic pain management solutions, evidenced by the wide adoption of its therapies in diverse clinical settings.
- Advanced R&D and Pipeline Development: By investing in robust research and development programs, along with strategic partnerships, Pacira continues to expand its portfolio and maintain competitive differentiation in the specialty pharmaceutical sector.
- Regulatory and Reimbursement Strategies: With products that have secured critical reimbursement designations, Pacira enhances market access for its non-opioid therapies across different healthcare settings. This strategic emphasis supports clinician adoption and broader patient access.
Clinical and Commercial Significance
The company's focus on non-opioid pain management comes at a time when reducing opioid dependency is an urgent priority in healthcare. By developing treatments that not only manage pain effectively but also minimize opioid consumption, Pacira is addressing a key public health challenge. Its clinically validated products have been incorporated into pain management protocols in hospitals and outpatient settings alike, offering enduring benefits for patients and healthcare providers.
Innovative Edge and Future Pipeline
Pacira’s utilization of advanced drug delivery systems, such as multivesicular liposomes and precise cryoneurolysis, underscores its commitment to innovation. These technologies not only improve therapeutic outcomes but also facilitate streamlined billing and regulatory approval processes through established coding systems. With an evolving pipeline that includes gene therapy approaches, the company is poised to expand its reach into additional therapeutic areas, addressing unmet needs in the treatment of chronic and musculoskeletal pain.
Competitive Landscape and Differentiators
In a competitive market, Pacira differentiates itself through its deep expertise in non-opioid pain management and its commitment to technological advancements. The integration of robust clinical data, strategic reimbursement initiatives, and a focus on delivering sustained therapeutic benefits positions the company as a trusted innovator among healthcare practitioners. Unlike traditional pain management solutions that rely heavily on opioids, Pacira’s products are designed to provide effective relief with reduced risk of dependency, offering a clinically superior alternative in the evolving landscape of pain management.
Conclusion
With a comprehensive portfolio that spans commercial-stage products and a promising pipeline, Pacira BioSciences Inc stands as a key player in the specialty pharmaceutical industry. Its ongoing commitment to developing non-opioid pain therapies, underpinned by advanced drug delivery technologies and rigorous clinical validation, ensures that it remains an authoritative source of innovation and expertise in pain management and regenerative health.
Pacira BioSciences announced topline results from its Phase 3 STRIDE study for EXPAREL, which failed to meet the primary endpoint of pain reduction from 0 to 96 hours compared to bupivacaine HCl. However, significant reductions in pain and opioid consumption were observed from 24 to 96 hours (p<0.01) and cumulative pain scores from 12 to 96 hours (p<0.02). Safety results showed no serious adverse events. The company plans to further analyze the data and discuss next steps with the FDA, emphasizing EXPAREL's potential in opioid-sparing pain management.
PACIRA BIOSCIENCES, INC. (NASDAQ: PCRX) will present at the 2021 Jefferies Virtual Healthcare Conference on June 1, 2021, at 9:30 AM ET. The event can be accessed via the company's website, with a replay available for two weeks after the presentation. Pacira is a leader in non-opioid pain management, known for its long-acting local analgesic EXPAREL®, launched in April 2012. The company aims to reduce opioid reliance and enhance patient care through innovative solutions, including the iovera°® cryoanalgesia device acquired in 2019.
Pacira BioSciences has received a Notice of Allowance from the USPTO for a patent regarding its EXPAREL manufacturing process, extending protection until January 22, 2041. This patent is a key component of the company's strategy to maintain market exclusivity for EXPAREL, a non-opioid pain management solution. The company has invested over $100 million in developing a more efficient manufacturing method. Additionally, Pacira is awaiting FDA approval for its new manufacturing process, with a PDUFA date set for August 6, 2021.
Pacira BioSciences, Inc. (NASDAQ: PCRX) will present at the 2021 RBC Capital Markets Global Healthcare Conference on May 18, 2021, at 10:20 AM ET. The virtual event will feature live audio accessible via the company’s website. A replay will be available for two weeks post-event.
Pacira is a leader in non-opioid pain management solutions, known for its long-acting local analgesic, EXPAREL®, which was launched in April 2012. In 2019, the company expanded its portfolio by acquiring the iovera°® system, enhancing its commitment to innovative pain management.
Pacira BioSciences reported preliminary unaudited net product sales for April 2021, achieving $43.1 million for EXPAREL and $1.5 million for iovera°. April's average daily sales of EXPAREL reached 449% of April 2020, driven by a recovery in elective surgeries as COVID-19 restrictions eased. CEO Dave Stack highlighted the growing demand for non-opioid pain management solutions. However, the company continues to face challenges due to the pandemic, which impacted elective surgical procedures. Monthly sales updates will be provided until clearer trends emerge.
Pacira BioSciences (PCRX) reported robust Q1 2021 results with total revenues of $119 million, up from $105.7 million in Q1 2020. GAAP net income reached $10.4 million or $0.24 per share, compared to $8.2 million or $0.19 last year. EXPAREL sales surged to $114.7 million, a notable increase from $101.3 million. The company experienced rising operational expenses at $99.6 million. Pacira continues to navigate COVID-19's impact on elective surgeries, with a strong outlook as recovery progresses.
Pacira BioSciences, Inc. (NASDAQ:PCRX) will release its first quarter financial results on May 4, 2021, before U.S. markets open. The company will host a live conference call at 8:30 a.m. ET to discuss these results. Interested parties can participate by dialing 1-877-845-0779 (domestic) or 1-720-545-0035 (international) with passcode 8238109. The call will be available for replay for one week. Pacira is known for its commitment to non-opioid pain management, notably through its long-acting analgesic EXPAREL® and the iovera°® cryoanalgesia device.
Pacira BioSciences, Inc. (Nasdaq: PCRX) has announced a $3 million investment in Spine BioPharma via a convertible note, aimed at advancing Spine's lead candidate, Remedisc™, a novel therapeutic for degenerative disc disease. An additional $7 million investment is contingent upon achieving specific milestones. This initiative aligns with Pacira's commitment to non-opioid pain management, targeting the underlying causes of degenerative disc disease to improve patient outcomes. Remedisc is expected to enter Phase 2/3 trials later this year.
Pacira BioSciences, Inc. (Nasdaq: PCRX) has filed a lawsuit against the American Society of Anesthesiologists (ASA) over misleading studies published in their journal regarding EXPAREL (bupivacaine liposome injectable suspension), which claim it is not effective for pain management. The lawsuit seeks damages and retraction of the articles, accusing the ASA of publishing scientifically unsound conclusions while failing to disclose financial conflicts of interest. Pacira aims to remove these misleading materials to prevent confusion among healthcare stakeholders.
Pacira BioSciences (Nasdaq: PCRX) reported preliminary unaudited net product sales for Q1 2021: $114.7 million for EXPAREL and $3.3 million for iovera°. March sales reached $44.3 million for EXPAREL, marking a significant year-on-year increase. The company highlights U.S. regulatory approval for EXPAREL in pediatrics and a trend towards outpatient care, despite ongoing COVID-19 impacts on elective surgeries. Pacira plans to provide monthly sales updates to maintain transparency.